Founded in 1999, Isogenis, Inc. is a Denver, CO
regenerative medicine company advancing novel cell and gene-based therapies
for restoring function of damaged organs and tissues. To overcome the
interference of the immune system in the success of organ/tissue replacement
and gene therapy, the company created and patented the only, fully deleted,
helper-independent Adenoviral vector that mitigated the immune response risk
inherent in early generation Adenoviral vectors.
Isogenis has applied its core technology in the fields of transplantation, gene
therapy, tissue engineering and vaccines. Successfully transplants without any
adjuvant immune suppressing drugs (such as cyclosporine or FK506) include:
organs (pancreatic islets); tissues – engineered skins (incl. heart & lung tissue);
cell preparations (hepatocytes); and, most recently, large organs (kidneys).